LIVMARLI (maralixibat chloride) by Mirum Pharmaceuticals is (ibat). Approved for cholestatic pruritus in patients 3 months of age, older with alagille syndrome (algs), cholestatic pruritus in patients 12 months of age and 1 more indications. First approved in 2025.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
LIVMARLI (maralixibat chloride) is an oral small-molecule ileal bile acid transporter (IBAT) inhibitor approved for cholestatic pruritus in pediatric patients with Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). It reduces bile acid reabsorption from the terminal ileum, decreasing serum bile acid levels and ameliorating pruritus symptoms. The mechanism of pruritus relief is not fully understood but is associated with inhibition of IBAT-mediated bile salt reuptake.
Recent April 2025 launch positions this as a growth-stage product with emerging team expansion needs in commercial and medical functions.
(IBAT). It decreases the reabsorption of bile acids (primarily the salt forms) from the terminal ileum . Pruritus is a common symptom in patients with ALGS or PFIC and the pathophysiology of pruritus in patients with ALGS or PFIC is not completely understood. Although the complete mechanism by…
Worked on LIVMARLI at Mirum Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome in the European Union (LEAP-EU)
Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moLIVMARLI represents a launch-stage orphan product with 30 linked job openings primarily at director and manager levels across R&D, quality, and commercial functions. Career opportunities are concentrated in scaling post-launch operations, establishing reimbursement strategies, and building medical affairs infrastructure for a pediatric rare disease franchise.
30 open roles linked to this drug